Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurochem ; 85(5): 1109-16, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12753070

ABSTRACT

Prolonged hypoxia exerts profound effects on cell function, and has been associated with increased production of amyloid beta peptides (A beta Ps) of Alzheimer's disease. Here, we have investigated the effects of chronic hypoxia (2.5% O2, 24 h) on capacitative Ca2+ entry (CCE) in primary cultures of rat type-I cortical astrocytes, and compared results with those obtained in astrocytes exposed to A beta Ps. Chronic hypoxia caused a marked enhancement of CCE that was observed after intracellular Ca2+ stores were depleted by bradykinin application or by exposure to thapsigargin (1 microM). Exposure of cells for 24 h to 1 microM A beta P(1-40) did not alter CCE. Enhancement of CCE was not attributable to cell hyperpolarization, as chronically hypoxic cells were significantly depolarized as compared with controls. Mitochondrial inhibition [by FCCP (10 microM) and oligomycin (2.5 microg/mL)] suppressed CCE in all three cell groups, but more importantly there were no significant differences in the magnitude of CCE in the three astrocyte groups under these conditions. Similarly, the antioxidants melatonin and Trolox abolished the enhancement of CCE in hypoxic cells. Our results indicate that chronic hypoxia augments CCE in cortical type-I astrocytes, a finding which is not mimicked by A beta P(1-40) and appears to be dependent on altered mitochondrial function.


Subject(s)
Astrocytes/metabolism , Calcium/metabolism , Cell Hypoxia/physiology , Cerebral Cortex/cytology , Hypoxia, Brain/metabolism , Amyloid beta-Peptides/pharmacology , Animals , Animals, Newborn , Astrocytes/cytology , Astrocytes/drug effects , Bradykinin/pharmacology , Calcium Channel Blockers/pharmacology , Cells, Cultured , Chelating Agents/pharmacology , Chronic Disease , Enzyme Inhibitors/pharmacology , Lanthanum/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mitochondria/drug effects , Peptide Fragments/pharmacology , Rats , Time
2.
J Neurochem ; 79(3): 699-712, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11701773

ABSTRACT

The effects of amyloid beta protein on voltage-gated K(+) channel currents were studied using the whole-cell patch-clamp technique. The 1-40 amino acid form of amyloid beta protein was applied to primary cultures of rat cerebellar granule and cortical neurones for 24 h. Both the unaggregated and aggregated forms of the peptide, which have differing biological activities, were used. In cerebellar granule neurones, 24-h pre-incubation with 1 microM unaggregated amyloid beta protein resulted in a 60% increase in the 'A'-type component of K(+) current. Increased delayed rectifier activity was Cd(2+)-sensitive and was presumed to be secondary to an increase in voltage-gated Ca(2+) channel current activity. Unaggregated amyloid beta protein had no effect on any component of the K(+) channel current in cortical neurones. One micromolar of aggregated amyloid beta protein had no effect on K(+) channel current in either cell type but reduced cell survival within 24 h as measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assays. The unaggregated form of amyloid beta protein had no neurotoxic effects when applied to either neurone type for up to 72 h. These data indicate that the unaggregated, non-pathological form of amyloid beta protein causes changes in the ion channel function of neurones, possibly reflecting a physiological role for the peptide.


Subject(s)
Amyloid beta-Peptides/toxicity , Ion Channel Gating/drug effects , Neurons/physiology , Peptide Fragments/toxicity , Potassium Channels/physiology , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/chemistry , Animals , Cadmium Chloride/pharmacology , Cells, Cultured , Cerebellum/cytology , Cerebral Cortex/cytology , Membrane Potentials/drug effects , Neurons/drug effects , Patch-Clamp Techniques , Peptide Fragments/chemistry , Potassium/metabolism , Rats , Solubility
3.
J Psychosoc Nurs Ment Health Serv ; 33(2): 24-6, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7769572

ABSTRACT

The study sought to find whether the discontinuation of fluoxetine (Prozac) 14 days prior to electroconvulsive therapy (ECT) results in positive patient outcome through improved safety and if the administration of Prozac in close proximity to ECT results in prolonged seizures. Patients who had ECT with 14 days' clearance of Prozac had no prolonged seizure activity. The awareness of possible complications resulting from Prozac and ECT soon became evident among the staff, and every effort was made to communicate this. Prozac has been promoted as being safer than tricyclic antidepressants because of its low cardiac toxicity and relative safety in overdoses.


Subject(s)
Depressive Disorder/nursing , Electroconvulsive Therapy , Electroencephalography/drug effects , Fluoxetine/adverse effects , Nursing Assessment , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Depressive Disorder/psychology , Drug Administration Schedule , Evoked Potentials/drug effects , Female , Fluoxetine/administration & dosage , Humans , Male , Reference Values , Risk Factors , Status Epilepticus/chemically induced , Status Epilepticus/nursing
SELECTION OF CITATIONS
SEARCH DETAIL
...